Molecular docking revealed that tormentic acid (4) interacts strongly with critical residues in the AChE active site, suggesting a mechanism similar to those of the reported anti-AChE agents used in Alzheimer’s disease management. The gene discussed is ACHE; the disease is Alzheimer disease.